New hope for brain hemorrhage patients: two drugs may be better than one
NCT ID NCT07144956
Summary
This study is testing whether adding a drug called cilostazol to the current standard treatment (nimodipine) helps people recover better after a life-threatening type of brain bleed called an aneurysmal subarachnoid hemorrhage. It will involve 630 patients in France who will receive either the new combination or the standard treatment plus a placebo for 14 days. The main goal is to see if patients have better functional recovery and independence six months later.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEURYSMAL SUBARACHNOID HEMORRHAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.